The FDA will publish information concerning advisory panel during this week
The FDA will publish information concerning advisory panel during this week On Friday November 21 the FDA, Food and Drug Administration, the American regulatory authority, will hold a advisory panel. The panel will discuss possible approval of RESTYLANE in the USA. Information on what will be dealt with by this panel will be published on the FDA's website at the latest 24 hours before the panel. The address is: www.fda.gov/ohrms/dockets/ac/cdrh03.html. On February 10 Q-Med announced the divesture of the North American business with regard to RESTYLANE, RESTYLANE Fine Lines and RESTYLANE